Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study.

Transl Psychiatry · 2022 · PMC9681874 · PMID 36414626

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

showed a trendno p-value reported

In initial analyses of the exploratory cognitive endpoint in the phase 2 EMERGENT-1 study, KarXT showed a trend towards greater improvement in cognitive performance relative to placebo over the course of 5 weeks of treatment but did not reach statistical significance.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.